Outpatient CD19-directed CAR T-cell therapy is feasible in patients of all ages
Br J Haematol
.
2023 Nov;203(4):688-692.
doi: 10.1111/bjh.19090.
Epub 2023 Aug 29.
Authors
Andrew Ly
1
,
Khaled Sanber
2
,
Hua-Ling Tsai
2
,
Angela Ondo
2
,
Kathy Mooney
2
,
Audra Shedeck
2
,
Julie Baker
2
,
Philip Hollingsworth Imus
2
,
Nina Wagner-Johnston
2
,
Tania Jain
2
Affiliations
1
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
2
Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
PMID:
37642134
DOI:
10.1111/bjh.19090
No abstract available
Publication types
Letter
MeSH terms
Antigens, CD19
Humans
Immunotherapy, Adoptive* / adverse effects
Outpatients*
Receptors, Antigen, T-Cell / genetics
Substances
Receptors, Antigen, T-Cell
Antigens, CD19